Archive by Author

The Code Lab visits Tel Aviv!

8 Apr

In February, 10 of us from the Code Lab visited Adi Stern’s lab in Tel Aviv, Israel. It was stressful to organize the trip (filling out so many forms, waiting for permission, finding reasonably priced tickets…), but now that we’ve done it I think it was totally worth it. The trip was really good for the lab and for our research. We are grateful to NSF for funding the trip (as part of a collaborative grant between the two labs), to everyone in Adi Stern’s group for hosting us and to the folks at SFSU who helped us (and are still helping us) with the administrative side of this trip!

Here are the best things from the trip:

1. We bonded as a lab!

Emily: One of the things I enjoyed the most about our trip was getting to know and meet people. There are many different individuals in our lab who I don’t know very well and this trip was a great opportunity to spend time with them!

Anjani: We were mostly together as a group during the trip and it made our bonding stronger than what we had when we left SFO.


Jasmeen, Anjani, Caroline, Geo, Stuart, Ryan (all SF)

2. We got to know our current and future collaborators from Tel Aviv and learned about their research.

Caroline: One thing I really liked about the trip was how welcoming and organized the Stern lab was even though we arrived sooner than initially planned. I got really excited seeing the HeLa cells and hearing about the different projects revolving around them. Olivia: I really enjoyed talking to Talia about her research on the Tilapia virus. This virus is found in both wild and farmed tilapia. I found the questions she was asking interesting because it affects people all over the world.

Ryan: Everyone was very cool and super nice.  


Caroline Solis (SF), Talia Kustin (Tel Aviv), Moran Meir (Tel Aviv), Anjani Pradhananga (SF), Jasmeen Kaur (SF).

3. We presented our work and got useful feedback.

Olivia: Sometimes it feels like I haven’t been able to finish or see a product, but I used my old poster that I had created for the COSE showcase (…) and found that I actually accomplished the aims/next steps. It was a nice feeling to learn that I have done something as I was updating my poster.

Kaho: I really enjoyed talking to Adi, Maoz and Sherry about research. The discussion we had was helpful and gave me clearer directions for the next steps of my research, and it was great to find out we have such cool collaborators!

Ryan: I also loved meeting the Tel Aviv lab because it made me see out research, not only from the dry lab perspective, but also from the wet lab side too.


Oded Kushnir (Tel Aviv) and Ryan Winstead (SF) look at a poster.

4. Visiting new cities and a foreign country

Emily: I was glad to see that Tel Aviv had a vibrant and openly queer community.

Getting to see the historical sites was equally important to me. Though I am not a fan or organized religion, (…), I learned many of the stories from the old and new testament, so seeing the actual places where they occurred was really cool. My grandma would have been so happy to see my pictures and hear about everything, and though she is gone now, she was in my heart the whole time.

Ryan: At first, I was very nervous about traveling so far from home. However, as soon as I was on board the plane, I felt excited about it. Tel Aviv was an amazing city and seeing it and the university was rewarding.


The Code Lab with our Tel Aviv guides Danielle Miller and Omer Tirosh from the Stern Lab. Clockwise from Anjani (taking the selfie), Caroline, Olivia, Geo, Emily, Danielle Miller, Omer Tirosh, Ryan, Stuart, Jasmeen, Kaho.

5. We enjoyed the food!

Stuart: Trying out new foods and deserts were a blast at dinner.


Shakshouka is a dish of eggs poached in a sauce of tomatoes, chili peppers, and garlic, commonly spiced with cumin, paprika, cayenne pepper, and nutmeg.

What we didn’t like as much

There were only a few things we didn’t like. Some of the students had never had a jet lag before and they hated it. We also didn’t like when we felt cheated by taxi-drivers or bartenders and we were sad to see and feel the tension between different groups in Jerusalem. One thing that we’ll keep in mind for our next trip is to schedule more time for the posters.

But all in all it was a fun, interesting and memorable trip!


The Code Lab and the Stern Lab. Front: Pleuni Pennings(SF), Yaara Ben Ari (Tel Aviv), Gal Goldman (Tel Aviv), Jasmeen Kaur (SF), Kaho Tisthammer (SF), Adi Stern (Tel Aviv), Tal Zinger (Tel Aviv), Olivia Pham (SF). Standing: Danielle Miller (Tel Aviv), Sherry Harari (Tel Aviv), Talia Kustin (Tel Aviv), Maoz Gelbart (Tel Aviv), Oded Kushnir (Tel Aviv), Caroline Solis (SF), Ryan Winstead (SF), Stuart Castaneda (SF), Anjani Pradhananga (SF), Geo Pineda (SF), Emily Fryer (SF)



The magic 8 ball in Python

28 Feb

When different people go into computer science, different tools will be built!

Maybe you have heard of the Tampon Run game? Tampon Run is a game that was built by two teenage girls who learned coding in a summer program. Obviously, you are more likely to get computer games about tampons when women or girls build games then when men build games! This is just one reason why we need more diversity in computer science.

In my Intro to Programming class last semester, students could make a video as a final project. Natasha Crawford, Destinee Lanns and Niquo Ceberio are Master’s students in the Biology Department at SFSU. As their final project, they made a video about a a computer program that works like a Magic 8 Ball. They ask: “Will my boyfriend propose to me?”


Niquo told me that she got the idea for the Magic 8 Ball program from her mom who used to have a Magic 8 Ball a long time ago. Now she can use the Python version!

In the video, Niquo, Destinee and Natasha first explain how to use the Python Magic 8 Ball. Then they go on to explain how they use strings and functions in the program.

I love love love how they created this program and made a video about it. They connected the CS class to things that are important or fun to them and with an audience in mind that is probably young and female.

I hope you enjoy the video and share it with a budding coder in your world.

Wu and Watterson’s Theta*?

10 Feb

If you are doing population genetics, you probably heard of Watterson’s theta.
The paper where Watterson introduced theta is a classic. It is cited more that 3000 times.

Even if Watterson (1975) was a single-author paper, Watterson wasn’t working alone on this project. In the acknowledgments he says “I thank Mrs. M. Wu for help with the numerical work, and in particular for computing Table I.” In a similar situation in 2019, she would have likely gotten co-authorship on this paper and a PhD after a few papers. We would all have known the paper as Wu and Watterson (1975).

Screenshot 2019-02-10 16.04.53

I only know this story because a group of researchers from SF State and Brown University, including my amazing friend and office neighbor Dr Rori Rohlfs, did a study on “Acknowledged Programmers.”

Professor Margaret Wu

Margaret Wu was a programmer in the 70s, at a time when programming was often a job for women. She didn’t get authorship on Watterson (1975) and other papers she worked on, but much later, she did get a PhD and became a very successful professor.

If you would like to learn more about Margaret Wu, have a look at this insightful interview:

Here is a video with her about the PISA rankings for countries’ educational systems: .

Paper and video on acknowledged programmers in theoretical population genetics

If you’d like to read more on acknowledged programmers in theoretical population genetics, have a look at the paper by Rori Rohlfs, Emilia Huerta-Sanchez and their students Samantha Dung, Andrea López, Ezequiel Lopez-Barragan, Rochelle-Jan Reyes, Ricky Thu, Edgar Castellanos and Francisca Catalan.

Plus!!! They made a really neat video about their project:


Here is a picture with most of the authors of the Genetics paper.


Authors of the paper in Genetics on Acknowledged Programmers: Illuminating Women’s Hidden Contribution to Historical Theoretical Population Genetics, Dung et al 2019.


* “Wu and Watterson’s Theta” was suggested by Tim Downing in a tweet.

Sequential evolution of HIV drug resistance against two-drug treatments

1 Feb

Together with Alison Feder (UC Berkeley), I am writing a paper about the history of HIV drug resistance evolution. In the paper, we focus on triple-drug therapies and we decided to leave out a nice story about two-drug therapies. It’s one of those cases where I really like the story and the data, but it just doesn’t fit in the paper we are trying to write. So, here it is, not peer-reviewed, not even on the BioRxiv, just on my blog.


Based on data from Picard et al 2001. Viral populations in patients acquire 3TC resistance first and AZT resistance later when treated with AZT and 3TC.

In 1987, the first RT inhibitor for treatment of HIV was FDA approved: zidovudine or AZT. Its claim to fame is mostly that it didn’t work. The virus became resistant quickly in almost every patient. In the first half of the 1990, other RT inhibitors were approved: DDI, D4T and 3TC. Now it was possible to combine drugs in two-drug (and even 3-drug) combinations. I want to focus here on the two-drug combinations.

One combination that was used was 3TC+AZT. HIV needs two mutations to become resistant to both drugs (there is no single mutation that makes the virus resistant to both).

Prediction: double mutants take over

Evolutionary biologists who were working on HIV drug resistance at the time predicted that drug resistance would evolve easily against these two-drug treatments (Ribeiro et al 1998), and this was indeed what happened. However, the reasoning for their prediction doesn’t hold. Let me explain. They made their prediction based on ideas about mutation-selection balance: with a large enough population size and high enough mutation rate, they expected that double mutants would be present as standing genetic variation in all patients. Therefore, they predicted that doubly resistant strains would take over the viral populations quickly. However, if we look at data from patients in clinical trials, this is not what we see happening.

What do the data show?

The dynamics of acquired drug resistance among patients on 3TC+AZT is evident from clinical trial data. In a study from 2001 (Picard et al, JID), all 21 patients treated with 3TC+AZT had developed resistance to 3TC (but not AZT!) after 24 weeks of treatment (see figure). By week 48, half of the patients who were still in the study had also acquired various AZT resistance mutations. Similar results were reported in another study (Larder, Kemp and Harrigan, 1995): after 8 weeks, 95% of patients were 3TC resistant (M184V), but none were AZT resistant. However, after 24 weeks, 25% of the patients had AZT resistance as well. In both of these examples, drug resistance mutations were fixed sequentially, with 3TC resistance arising before AZT resistance.

Two surprises

So, while the predictions based on evolutionary theory predicted rapid spread of double mutants, what we saw was first, the rapid spread of a single mutant and later, the spread of the second mutant on the background of the first. There are two surprises here. First, there is the surprise that the double mutant was not present as standing genetic variation in most patients (I think this is because early pop gen papers on HIV overestimated the effective population size of HIV), and second, there is the surprise that it was possible for a single mutant to spread in the face of two-drug treatment. We think that this last phenomenon has to do with the existence of compartments in the human body (Moreno-Gamez, 2015), where some drugs do not penetrate in all compartments. The drug that has the best penetration into compartments like the brain or the lymphatic tissue is therefore vulnerable to drug resistance evolution when it encounters the virus without the support of the second or third drug.

Take-home message

A model that makes the correct prediction may still be wrong.

Thanks to Sarina Qin for making the figure for me!


Larder, B. A., Kemp, S. D. and Harrigan, P. R. (1995) ‘Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.’, Science (New York, N.Y.). American Association for the Advancement of Science, 269(5224), pp. 696–9. doi: 10.1126/SCIENCE.7542804.

Moreno-Gamez, S., Hill, A.L., Rosenbloom, D.I.S., Petrov, D.A., Nowak, M.A., Pennings, P.S. 2015. Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multi-drug resistance. PNAS. (22 citations)

Picard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis. 2001;184:781–784.

Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. Aids. 1998;12(5):461–5.

Scientist spotlight : Jazlyn Mooney, PhD student UCLA

25 Jan

jazlynmooneyJazlyn Mooney grew up in Albuquerque New Mexico. She went to high school and college there too (Eldorado High School and University of New Mexico).

Sketching science created a lasting interest

I became interested in science in middle school. I had a science teacher, Mr. Pecknik, who made us draw everything we learned about (from central dogma to phylogenies) for class. So we kept a sketch book for our science class and I thought it was super cool.”

Not “cut out for MD/PhD” ?

Becoming a researcher didn’t always seem possible for Jazlyn. One summer, when she was an undergrad, she participated in an MD/PhD prep program. At the end of the summer, her summer advisor told her that she wasn’t cut out to be MD or PhD! Fortunately, she didn’t listen to him but instead listened to her other undergrad advisor, her family and herself and decided to continue her path to become a scientist! She did research as an undergraduate and then applied to PhD programs.

The history of Latin American populations

Jazlyn is now a PhD student at UCLA in the lab of Dr. Kirk Lohmueller and works to better understand the history of human populations using genetic data. She recently published a paper entitled: “Understanding the Hidden Complexity of Latin American Population Isolates.” In this paper she showed how Costa Rican and Columbian people are descended mostly from European males and Amerindian females, and a small number of African individuals.

The field that uses genetic data to understand the history of populations is called “population genetics”. Jazlyn got interested in population genetics when she was an undergrad and got an opportunity to do research with Dr Jeff Long.

Learning new things and presenting at meetings

Jazlyn loves learning new things and her favorite part of being a researcher is that it allows her to learn new things and create new knowledge. Jazlyn has presented her work at many conferences including : University of Chicago Research Forum, the meeting of the American Society for Human Genetics, the Bay Area Population Genomics meeting at UC Santa Cruz in 2018.


Link to paper about the history of people in Costa Rica and Columbia

Link to a free “prepring” version of the same paper

Tacos, R and Twitter

Jazlyn’s favorite coding language: R

Jazlyn’s favorite food: Tacos

Jazlyn’s Twitter handle: @Jazlyn_Mooney

Boltz et al 2011 on standing genetic variation and HIV drug resistance

14 Jan

I am re-reading and older but beautiful paper on drug resistance evolution and standing genetic variation by Valerie Boltz and colleagues (Boltz et al 2011, PNAS). I wanted to share this story because it is a nice example of population genetics at work in a relevant system: HIV during antiviral treatment.

Boltz and colleagues look at the risk of virology failure or death in women on first-line HIV therapy who had been previously treated with single-dose Nevirapine (sdNVP) and correlate the risk with the observed frequency of drug resistance mutations prior to first-line treatment.

OK, that’s a long and ugly sentence. I’ll try to explain. So there is a group of women who are all HIV-positive. They have recently given birth to a baby and during childbirth, they were treated with sdNVP. This simple (and cheap) treatment reduces the risk that the baby gets HIV infected during birth (it is not recommended any more as better options are now available). One drawback of the sdNVP treatment is that the women end up with an increased frequency of drug resistance mutations in their viral population (specifically mutations K103N, Y181C and G190A in RT). Now, half-a-year or more later, the women start “normal” triple-drug therapy for their own health. They are in a clinical trial and some of them start NNRTI-based treatment whereas others start PI/r-based treatment. Since sdNVP is an NNRTI, the researchers were (rightfully) worried that the viral populations in these women have standing genetic variation for NNRTI resistance – more than other people who had never been treated with sdNVP. The paper looks at the women in both arms of the trial, but I am only interested in the NNRTI arm.

So what Boltz and colleagues did was: use allele-specific PCR to quantify the amount of standing genetic variation for NNRTI drug resistance in these women’s viral populations before they started their first-line therapy (but after the sdNVP) and then correlate with how well the treatment worked in these women. During treatment, the researchers focus on the occurrence of two bad outcomes: death and virologic failure. Death is not so common in this trial (but does occur, 4 of 241 women die in the three years of the trial) – virologic failure is more common (38 women). Virologic failure means that there is detectable viral replication in the blood even though the person is on treatment. Often, virologic failure is caused by drug resistance.

More SGV -> more virologic failure

Not surprisingly (but very cool nevertheless): more standing genetic variation prior to treatment is associated with a higher probability of virologic failure. Their (and my) interpretation: Standing Genetic Variation matters for drug resistance evolution.

This figure (fig 3 in the original paper) shows that women with >1% of the viral population carrying a resistance mutation have a much higher probability of virologic failure or death. The plot (a Kaplan-Meier plot) shows time in weeks on the x-axis and the fraction of women without failure or death on the y-axis. One way to read such a graph is to focus on one point on the x-axis. After 72 weeks, about 85% of the women with no detected drug resistance mutations are doing well on their treatment. 77% of the women with drug resistance mutations at a frequency <1% are doing well. 53% of the women with drug resistance mutations at a frequency between 1-10% are doing well and 49% of women with drug resistance mutations at a frequency of more than 10% are doing well.



Plotting the number of women in the US congress

10 Nov

I wrote a simple python script to plot the number of women in congress and used it in my intro CS class this week. Two reasons:

1. That jump in 2019 is so good!!! This is helping me get over 2016.

2. We shouldn’t have to choose between activism and science.

Data from wikipedia on Nov 10th (numbers may still change when final races are called).

If anyone has similar data for the number of people of color in congress, I would like to plot that too!